GlassScriptPhysician profile
Mehdi Shaaf
NPI 1952476004
$4,395.18
in general payments reported to CMS, 2019-2025
19 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $122 · 2021: $1,159 · 2022: $682 · 2023: $1,034 · 2024: $83.88 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,777.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,942.35 | 2019-2025 | Clareon, Tryptyr, Centurion |
| Rxsight INC | $536.69 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sight Sciences, INC. | $361.13 | 2021-2024 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $239.52 | 2023 | Eylea, Eylea Hd |
| Dompe US, INC. | $237.27 | 2021-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $206.72 | 2019-2021 | |
| Ivantis, INC | $163.59 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $146.52 | 2022-2023 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $125.00 | 2023 | Miebo |
| Apellis Pharmaceuticals, INC. | $114.82 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.68 | 2019 | |
| Glaukos Corporation | $84.34 | 2019-2022 | |
| Amgen INC. | $34.38 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $30.06 | 2021-2022 | |
| Halozyme INC | $28.22 | 2019-2024 | Hylenex Recombinant |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $17.91 | 2023 | Tepezza |
| Abbvie INC. | $17.64 | 2023 | Durysta |
| Allergan, INC. | $15.51 | 2020 | |
| Travere Therapeutics, INC. | $0.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehdi Shaaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.